Hyphens Pharma International Limited, a leading Singaporean pharmaceutical and healthcare group, has announced a strategic partnership with Swiss company Louis Widmer SA to commercialise its Cerapro® MED Skin Barrier Cream across six European countries. This agreement, which includes Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands, aims to introduce the innovative eczema treatment to European markets by 2026.
Cerapro® MED Skin Barrier Cream, a patented formulation, is designed to lower skin pH and restore the skin barrier, addressing key factors of atopic dermatitis, a common form of eczema. The product has been approved as a CE-marked medical device under the European Medical Device Regulation, offering a novel treatment option for patients. Louis Widmer, known for its high-quality dermatology products since 1960, will promote Cerapro® to dermatologists and paediatricians in the designated regions.
Hyphens Pharma will receive an upfront fee and royalties on sales as part of the licensing agreement. Lim See Wah, Chairman and CEO of Hyphens Pharma, expressed enthusiasm about the collaboration, stating, “This milestone partnership with Louis Widmer underscores our commitment to innovation and patient care.”
Annemarie Widmer, CEO of Louis Widmer, added, “We are excited to partner with Hyphens Pharma to introduce Cerapro® to our markets, offering patients a clinically proven solution for atopic dermatitis.”
This collaboration marks a significant step for Hyphens Pharma in expanding its reach into the European market, potentially enhancing patient outcomes with its science-backed dermatological solutions.
